Cover Image
市場調查報告書

imatinib mesylate的中國市場

Investigation Report on China Imatinib Mesylate Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 332301
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
imatinib mesylate的中國市場 Investigation Report on China Imatinib Mesylate Market, 2010-2019
出版日期: 2015年06月04日 內容資訊: 英文 20 Pages
簡介

imatinib mesylate,是由Novartis所開發的蛋白酪氨酸激酶抑制劑。該藥由於其創新的抗腫瘤機制,以Gleevec這個商標藥品名在2001年5月10日取得FDA的迅速核准。現在已成為全球80個以上國家核可的慢性骨髓性白血病治療藥。中國市場自2002年4月推出以來其銷售額急速擴大,到2014年已達到5億3200萬人民幣的規模。

本報告提供中國的imatinib mesylate市場規模與今後預測,提供您主要製藥公司及劑型別市場佔有率,銷售價格等資訊。

第1章 imatinib mesylate的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國imatinib mesylate的市場簡介

  • imatinib mesylate的專利及核準情況
  • 主要製藥公司
  • 市場規模
  • 走私的imatinib mesylate

第3章 中國imatinib mesylate銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國imatinib mesylate的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國imatinib mesylate的劑型的相關調查

  • 劑型別市場佔有率:以銷售額為準
  • 劑型別市場佔有率:以銷售量為準

第6章 中國醫院的imatinib mesylate的標準價格

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Ge Ni Ke)
  • Hansoh Pharmaceutical (Xin Wei)
  • Novartis (Swiss) (Gleevec)

第7章 中國市場中imatinib mesylate的主要製藥公司

  • Hansoh Pharmaceutical; Chia Tai Tianqing Pharmaceutical Group Co., LtdNovartis

第8章 中國imatinib mesylate的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1506193

The mortality of leukemia ranks sixth among tumors while its incidence and mortality ranks first among malignant tumors for teenagers. The incidence of leukemia reaches two age peaks: 0-9 years old and above 60 years old.

Imatinib Mesylate was a tyrosine kinase inhibitor developed by Novartis. On May. 10, 2001, Imatinib Mesylate got FDA's express approval with the trade name of Gleevec due to its groundbreaking anti-tumor mechanism. On Dec. 23, 2009, Imatinib Mesylate gained its status as the first-line treatment for chronic myelogenous leukemia under FDA's approval. And now it has been approved for treatment of chronic myelogenous leukemia in more than 80 countries around the world.

After entering Chinese market on Apr. 17, 2002, Imatinib Mesylate has developed fast with annual sales reaching CNY 532 million in 2014 and CAGR reaching up to 42% during the period of 2005-2014. Currently, Imatinib Mesylate in the Chinese market is made by the following three companies: Novartis (Swiss), Chia Tai Tianqing Pharmaceutical Group Co., Ltd and Hansoh Pharmaceutical, among which Novartis has the largest market share of over 98% with sales value reaching up to CNY 523 million in 2014.

Imatinib Mesylate has accurate curative effects on chronic myelogenous leukemia despite its relatively high price. Chinese patients with low incomes were once sued for purchasing Imatinib Mesylate smuggled from India whose price is only 10% or less of that in Chinese market. As China's economy develops, people's income and purchasing power increases. Since an increasing number of patients are estimated to afford Imatinib Mesylate, its market size will expand further in China.

Readers can get at least the following information through this report:

  • market size of Imatinib Mesylate in China
  • major manufacturers of Imatinib Mesylate in the Chinese market and their market share
  • retail price of Imatinib Mesylate in China
  • market outlook of Imatinib Mesylate in China

The author suggests the following groups of people purchase this report:

  • manufacturers of leukemia drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Imatinib Mesylate

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Imatinib Mesylate in China

  • 2.1. Patent and Approval Status of Imatinib Mesylate in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size
  • 2.4. Smuggled Imatinib Mesylate in Chinese Market

3. Survey on Sales Status of Imatinib Mesylate in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Imatinib Mesylate in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Imatinib Mesylate in China, 2010-2014

  • 5.1. Share of Different Dosage Forms of Imatinib Mesylate by Sales Value
  • 5.2. Share of Different Dosage Forms of Imatinib Mesylate by Sales Volume

6. Reference Price of Imatinib Mesylate in Chinese Hospitals in 2014

  • 6.1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Ge Ni Ke)
  • 6.2. Hansoh Pharmaceutical (Trade Name: Xin Wei)
  • 6.3. Novartis (Swiss) (Trade Name: Gleevec)

7. Major Manufacturers of Imatinib Mesylate in Chinese Market, 2010-2014

Hansoh Pharmaceutical; Chia Tai Tianqing Pharmaceutical Group Co., LtdNovartis

8. Market Outlook of Imatinib Mesylate in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Imatinib Mesylate in China
  • Chart Approval Information of Imatinib Mesylate in China
  • Chart Sales Status of Imatinib Mesylate in China, 2010-2014
  • Chart Sales Value of Imatinib Mesylate in China, 2010-2014
  • Chart Sales Value of Imatinib Mesylate in Some Regions in China, 2010-2014
  • Chart Sales Volume of Imatinib Mesylate in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Imatinib Mesylate for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Imatinib Mesylate Made by Novartis in China, 2010-2014
  • Chart Sales Value and Market Share of Imatinib Mesylate Made by Hansoh in China, 2010-2014
  • Chart Sales Value and Market Share of Imatinib Mesylate Made by Chia Tai Tianqing in China, 2010-2014
  • Chart Sales Value and Market Share of Imatinib Mesylate Tablets in China, 2010-2014
  • Chart Sales Value and Market Share of Imatinib Mesylate Capsules in China, 2010-2014
  • Chart Price of Imatinib Mesylate Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Imatinib Mesylate Made by Hansoh Pharmaceutical in Some Chinese Cities in 2014
  • Chart Price of Imatinib Mesylate Made by Novartis (Swiss) in Some Chinese Cities in 2014
Back to Top